Samanta Sarti

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

Valentina Guarneri, Antonio Frassoldati, Alberto Bottini et al. · Journal of Clinical Oncology · 2012 · 366 citations · Full text

The impact of chemotherapy-induced nausea and vomiting on health-related quality of life

Enzo Ballatori, Fausto Roila, Benedetta Ruggeri et al. · Supportive Care in Cancer · 2006 · 140 citations

Quality Of Life, Oncology, Chemotherapy-induced Nausea +2

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

Valentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati et al. · The Oncologist · 2015 · 109 citations · Full text

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors

Alberto Farolfi, Elisabetta Melegari, Michele Aquilina et al. · Heart · 2013 · 106 citations

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

Maria Vittoria Dieci, Pierfranco Conté, Giancarlo Bisagni et al. · Annals of Oncology · 2019 · 94 citations · Full text